UNSPSC 51142429: Frovatriptan succinate

This classification denotes a serotonin agonist with the molecular formula C14H17N3O.C4H6O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D28J6W18HY, chemically known as 1h-carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (r)-, butanedioate (1:1) but more generally known as frovatriptan succinate, which bears US NIH Compound Identifier 152944. European Medicines Agency schedules Frovatriptan succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22174.

UNSPSC 51142429 Frovatriptan succinate is a Commodity code that nominally identifies a specific triptan migraine medication, but recent state and local procurement activity under this code does not reflect direct purchases of frovatriptan. Instead, the tagged opportunities show state and local health agencies procuring naloxone (opioid reversal), safe drug deactivation systems, and broader generic and OTC pharmaceutical supply through multi-state cooperative purchasing frameworks. The scope mismatch suggests either miscoding in the issuing bodies' tagging systems or that this Commodity code is being used as a proxy for pharmaceutical procurement more broadly. State health departments and their procurement officers—particularly in Texas and Minnesota—are the dominant issuing bodies, along with county health departments like Seminole County, Florida. The work involves establishing supply contracts for emergency pharmaceuticals, generic medications, and OTC products distributed through authorized wholesalers and delivered to county health facilities and state pharmacy benefit programs.

Recent opportunities span Florida, Texas, and Minnesota, with multi-state cooperative purchasing frameworks amplifying reach. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023 (note: date discrepancy in source), requiring quarterly deliveries to the Seminole County Community Health Building with a two-year term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting arrangements outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 with a due date of March 26, 2026 for generic multi-source pharmaceuticals and OTC products with distribution across participating state and local facilities including Oregon, requiring manufacturers to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026.